Revvity Q3 revenue comes in at $729 million
Pontos principais
- Revvity reported third-quarter 2026 revenue of $729 million, up 4.3% year over year, while adjusted earnings increased to $1.38 per share.
- Pro forma revenue rose 7% to $710 million, and Revvity shares gained approximately 5% in early trading following the earnings announcement.
- Revvity raised its full-year guidance, forecasting approximately $2.86 billion in pro forma revenue and adjusted earnings of $5.40–$5.45 per share.
Revvity (NYSE:RVTY) reported third-quarter 2026 revenue of $729 million, up from $699 million a year earlier, while raising its full-year guidance.
GAAP earnings from continuing operations increased to $0.56 per share from $0.41, while adjusted earnings rose to $1.38 from $1.18.
Pro forma revenue reached $710 million, up 7%, while Revvity forecast approximately $2.86 billion in full-year revenue and adjusted earnings of $5.40–$5.45 per share.
Following the announcement, the Revvity share price was up approximately 5% at $159.29 in early trading.
Revvity reported adjusted operating income of $209 million, up from $182 million, while its adjusted operating margin increased to 28.7% from 26.1%.
The company plans to divest its China Immunodiagnostics business by the end of 2027 and will hold an Investor Day on November 13, 2026.
